Buscar
Mostrando ítems 1-10 de 21
Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus
(American Association for Cancer Research, 2010-06)
The cytosine analogue decitabine alters hematopoietic differentiation. For example, decitabine treatment increases self-renewal of normal hematopoietic stem cells. The mechanisms underlying decitabine-induced shifts in ...
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
(John Wiley & Sons Inc, 2012-07)
Apoptosis genes, such as TP53 and p16/CDKN2A, that mediate responses to cytotoxic chemotherapy, are frequently nonfunctional in melanoma. Differentiation may be an alternative to apoptosis for inducing melanoma cell cycle ...
CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
(Nature Publishing Group, 2012-02)
The DNA hypomethylating drug decitabine maintains normal hematopoietic stem cell (HSC) self-renewal but induces terminal differentiation in acute myeloid leukemia (AML) cells. The basis for these contrasting cell fates, ...
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine
(American Society of Hematology, 2012-02)
The deoxycytidine analog decitabine (DAC) can deplete DNA methyl-transferase 1 (DNMT1) and thereby modify cellular epigenetics, gene expression, and differentiation. However, a barrier to efficacious and accessible ...
Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
(Nature Publishing Group, 2017-12)
Aberrant DNA methylation observed in cancer can provide survival benefits to cells by silencing genes essential for anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise ...
Abnormal Methylation of Histone Deacetylase Genes: Implications on Etiology and Epigenetic Therapy of Astrocytomas
(INT INST ANTICANCER RESEARCH, 2011)
Background: A growing body of evidence has revealed, the involvement of epigenetic alterations in the etiology of astrocytomas. In the present study, we aimed to evaluate the association of DNA methylation of histone ...
Decitabine bioproduction using a biocatalyst with improved stability by adding nanocomposites
(Springer, 2020-12)
A novel IDA-LaNDT derivative was able to reach the highest productivity in the biosynthesis of a well-known antitumoral agent called decitabine. However, the combination of two simple and inexpensive techniques such as ...
Preliminary safety analysis of an expanded access program for decitabine in subjects with myelodysplastic syndrome (MDS)
(Ferrata Storti Foundation, 2010-06-01)
Preliminary safety analysis of an expanded access program for decitabine in subjects with myelodysplastic syndrome (MDS)
(Ferrata Storti Foundation, 2010-06-01)
P53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia
(Nature Publishing Group, 2011-11)
Suppression of apoptosis by TP53 mutation contributes to resistance of acute myeloid leukemia (AML) to conventional cytotoxic treatment. Using differentiation to induce irreversible cell cycle exit in AML cells could be a ...